DB05225ExperimentalSmall molecule
AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is... It is being developed by Amira.
- Mechanism
- Curator reviewed
The exact mechanism of actions is not known, however, AM103 inhibits the 5-lipoxygenase-activiting protein (FLAP). This prevents the synthesis of LT, which normally triggers inflammation.
- Primary indication
- For the treatment of asthma and cardiovascular disease.Curator reviewed
- Code names
- AM103
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with AM103, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account